Results 31 to 40 of about 6,085 (188)

Pulmonary Large Cell Neuroendocrine Carcinoma

Pathology and Oncology Research, 2022
Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare subtype of malignant pulmonary tumor. The incidence rate of LCNEC was reported to be 0.3%–3% in lung cancers.
Lan Yang, Lan Yang, Lan Yang, Lan Yang, Ying Fan, Ying Fan, Ying Fan, Ying Fan, Hongyang Lu, Hongyang Lu, Hongyang Lu, Hongyang Lu   +11 more
doaj   +1 more source

Molecular Subtypes of High-Grade Neuroendocrine Carcinoma (HGNEC): What is YAP1-Positive HGNEC?

Frontiers in Bioscience-Landmark, 2022
Small cell lung cancer (SCLC) subtype classification, based on high-level expression of key transcriptional regulators; ASCL1 (SCLC-A), NEUROD1 (SCLC-N), POU2F3 (SCLC-P), and YAP1 (SCLC-Y), has recently been proposed.
Hitomi Kawai, Ryouta Matsuoka, Takeshi Ito, Daisuke Matsubara   +3 more
doaj   +1 more source

Large Cell Neuroendocrine Cancer (LCNEC) of Uterine Cervix

Ibrahim Medical College Journal, 1970
A rare type of cervical cancer was encountered as a neuroendocrine cancer of cervix. Clinically, the patient presented with bleeding per vagina. She refused biopsy in her first visit and did not come for follow up. However, after few months she came and since there was a polypoid growth from cervix, she was advised to undergo hysterectomy ...
Gehanath Baral, Reetu Sharma
openaire   +3 more sources

In-depth molecular analysis of combined and co-primary pulmonary large cell neuroendocrine carcinoma and adenocarcinoma [PDF]

, 2022
Up to 14% of large cell neuroendocrine carcinomas (LCNECs) are diagnosed in continuity with nonsmall cell lung carcinoma. In addition to these combined lesions, 1% to 7% of lung tumors present as co-primary tumors with multiple synchronous lesions.
Jan H. von der Thüsen, den Toom, T. Dorine, Hermans, Bregtje C.M., Esther C. van den Broek, Hillen, Lisa M., Coumans-Stallinga, C., den Toom, T.D., Ernst‐Jan M. Speel, Derks, Jules L., van der Baan, Irene, van Suylen, Robert Jan, Dubbink, Hendrikus J., Hermans, B.C.M., Dinjens, Winand N.M., Cecile Coumans‐Stallinga, Hermans, Bregtje C. M., Hendrikus J. Dubbink, van Suylen, Robert‐Jan, Dingemans, Anne‐Marie C., Coumans-Stallinga, Cecile, Van Suylen, Robert-Jan, Dinjens, Winand N. M., van der Baan, I., Irene van der Baan, van den Broek, Esther C., Dingemans, A.M.C., van den Broek, E.C., Speel, Ernst‐Jan M., Dinjens, W.N.M., Anne‐Marie C. Dingemans, Winand N. M. Dinjens, von der Thusen, Jan H., Dingemans, Anne-Marie C., Dingemans, Anne Marie C.; id_orcid, Bregtje C. M. Hermans, Timens, Wim, Peggy N. Atmodimedjo, Timens, W., Derks, J.L., Dingemans, Anne Marie C., Atmodimedjo, Peggy N., von der Thüsen, Jan H.; id_orcid, von der Thusen, J.H., Timens, Wim; id_orcid, Van Suylen, R.J., Robert‐Jan van Suylen, Coumans‐Stallinga, Cecile, Speel, Ernst-Jan M., Dubbink, Hendrikus J.; id_orcid, T. Dorine den Toom, Lisa M. Hillen, Atmodimedjo, P.N., Wim Timens, Speel, E.J.M., Jules L. Derks, Dubbink, H.J., Speel, Ernst Jan M.   +56 more
core   +3 more sources

Combined large cell neuroendocrine carcinoma, lung adenocarcinoma, and squamous cell carcinoma: a case report and review of the literature

Journal of Cardiothoracic Surgery, 2023
Background Combined large cell neuroendocrine carcinoma (C-LCNEC) has a poor prognosis and there is no consensus about the treatment regimen for both LCNEC and C-LCNEC patients. Case presentation The patient was a 47-year-old female who received surgical
Zirui Zhu, You Liu, Hengliang Xu, Haoyong Ning, Yanmin Xia, Leilei Shen   +5 more
doaj   +1 more source

Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities

Frontiers in Oncology, 2021
Large-cell neuroendocrine carcinomas of the lung (LCNECs) are rare tumors representing 1–3% of all primary lung cancers. Patients with LCNEC are predominantly male, older, and heavy smokers.
Miriam Grazia Ferrara, Miriam Grazia Ferrara, Alessio Stefani, Alessio Stefani, Michele Simbolo, Sara Pilotto, Maurizio Martini, Filippo Lococo, Emanuele Vita, Emanuele Vita, Marco Chiappetta, Alessandra Cancellieri, Ettore D’Argento, Ettore D’Argento, Rocco Trisolini, Guido Rindi, Aldo Scarpa, Stefano Margaritora, Michele Milella, Giampaolo Tortora, Giampaolo Tortora, Emilio Bria, Emilio Bria   +22 more
doaj   +1 more source

Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC) [PDF]

, 2018
Background: Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare tumor with high mutational burden. Two subtypes of LCNEC are recognized, the co-mutated TP53 and RB1 group and the TP53 and STK11/KEAP1 group.
Stallinga, C. M., Derks, J. L., Roemen, GM, Derks, JL, Thunnissen, E., Groen, H. J. M., den Bakker, Michael, Groen, HJM, Dingemans, A-M. C., den Bakker, M. A., Smit, EF, Dingemans, AMC, Groen, H. J. M.; id_orcid, Palga-Group, P., van Suylen, R. J., Hermans, B. C.M., Dingemans, A. -M. C., Speel, E. J. M., Groen, H. J.M., Broek, EC, Dingemans, A. M. C., Dingemans, A. M.C., van Suylen, RJ, Hermans, BCM, Hermans, B. C. M., Thunnissen, E, van den Broek, E. C., Hermans, B., Stallinga, CM, Roemen, G. M., Smit, E. F., Damhuis, RA, Speel, E. J., Speel, EJM, Dingemans, A.-M.C.; id_orcid, Speel, E. J.M., Damhuis, R. A., Thunissen, E.   +37 more
core   +2 more sources

Long‐term survivor of pulmonary combined large cell neuroendocrine carcinoma treated with nivolumab

Thoracic Cancer, 2020
Several authors have previously reported that patients with pulmonary combined large cell neuroendocrine cancer ( LCNEC) have a poor prognosis and there is no consensus on the treatment strategy for combined LCNEC as well as LCNEC.
Risa Oda, Katsuhiro Okuda, Yoriko Yamashita, Tadashi Sakane, Tsutomu Tatematsu, Keisuke Yokota, Katsuhiko Endo, Ryoichi Nakanishi   +7 more
doaj   +1 more source

N-staging in large cell neuroendocrine carcinoma of the lung: diagnostic value of [18F]FDG PET/CT compared to the histopathology reference standard

EJNMMI Research, 2021
Background Large cell neuroendocrine carcinoma of the lung (LCNEC) is a rare entity occurring in less than 4% of all lung cancers. Due to its low differentiation and high glucose transporter 1 (GLUT1) expression, LCNEC demonstrates an increased glucose ...
Hubertus Hautzel, Yazan Alnajdawi, Wolfgang P. Fendler, Christoph Rischpler, Kaid Darwiche, Wilfried E. Eberhardt, Lale Umutlu, Dirk Theegarten, Martin Stuschke, Martin Schuler, Clemens Aigner, Ken Herrmann, Till Plönes   +12 more
doaj   +1 more source

Successful Treatment of ALK-Positive Large-Cell Neuroendocrine Carcinoma of the Lung With Sequential ALK Inhibitors: A Case Report

JTO Clinical and Research Reports, 2023
ALK-positive large-cell neuroendocrine carcinoma (LCNEC) is an exceptionally rare form of lung cancer. The efficacy of ALK inhibitors in treating ALK-positive LCNEC remains unclear. Here, we report a case of ALK-positive LCNEC of the lung, which revealed
Takayuki Kobayashi, MD, Yuji Uehara, MD, Kageaki Watanabe, MD, Tsunekazu Hishima, MD, Yukio Hosomi, MD   +4 more
doaj   +1 more source